Table 2.

Anemia Incidence Rates and HRs Across Treatment Groups, Overall and Within Subgroups

Group	Placebo (n = 2887)	Canakinumab
		50 mg (n = 1892)	150 mg (n = 1973)	300 mg (n = 1931)	All Doses (n = 5796)
Total cohort
Incidence rate (events, n)	8.13 (690)	6.63 (380)	6.90 (412)	6.94 (406)	6.83 (1198)
HR (95% CI)	1 (reference)	0.83 (0.73-0.94)	0.84 (0.75-0.95)	0.85 (0.75-0.96)	0.84 (0.77-0.93)
Age
≥65 y
Incidence rate (events, n)	12.27 (322)	9.32 (180)	9.12 (179)	10.02 (188)	9.48 (547)
HR(95% CI)	1 (reference)	0.79 (0.66-0.95)	0.74 (0.62-0.89)	0.80 (0.67-0.96)	0.78 (0.68-0.89)
<65 y
Incidence rate (events, n)	6.28 (368)	5.26 (200)	5.82 (233)	5.48 (218)	5.52 (651)
HR(95% CI)	1 (reference)	0.85 (0.71-1.01)	0.92 (0.78-1.08)	0.87 (0.74-1.03)	0.88 (0.78-1.00)
eGFR
<60 mL/min/1.73 m2
Incidence rate (events, n)	15.67 (176)	12.51 (100)	11.45 (93)	12.93 (110)	12.31 (303)
HR (95% CI)	1 (reference)	0.85 (0.66-1.08)	0.74 (0.57-0.95)	0.84 (0.66-1.06)	0.80 (0.67-0.97)
≥60 mL/min/1.73 m2
Incidence rate (events, n)	6.99 (514)	5.68 (280)	6.19 (319)	5.92 (296)	5.93 (895)
HR(95% CI)	1 (reference)	0.82 (0.71-0.95)	0.88 (0.76-1.01)	0.84 (0.73-0.97)	0.85 (0.76-0.95)
Type 2 diabetes
Yes
Incidence rate (events, n)	11.30 (337)	9.15 (189)	8.68 (195)	8.62 (180)	8.82 (564)
HR (95% CI)	1 (reference)	0.83 (0.69-0.99)	0.77 (0.65-0.92)	0.76 (0.63-0.91)	0.79 (0.69-0.90)
No
Incidence rate (events, n)	6.42 (353)	5.21 (191)	5.83 (217)	6.00 (226)	5.68 (634)
HR (95% CI)	1 (reference)	0.82 (0.69-0.98)	0.90 (0.76-1.06)	0.93 (0.79-1.10)	0.89 (0.78-1.01)

eGFR = estimated glomerular filtration rate; HR = hazard ratio.